alopecia

Posts

Global Alopecia Market Size

Global Alopecia Market Size

/in /by

Global Alopecia Market Size

Alopecia Market was valued at USD 2.68 Billion in 2020 and is projected to reach USD 4.89 Billion by 2028, growing at a CAGR of 7.9% from 2021 to 2028.

Changing lifestyle and rising prevalence of androgenic and areata alopecia across the globe is primary factors for driving the growth of the Global Alopecia Market. Also, the rise in disposable income of the people and growing awareness regarding alopecia treatment is fueling the growth of the Global Alopecia Market. The Global Alopecia Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Alopecia Market Definition

Alopecia areata is also called spot baldness. It is a medical condition in which hair is lost from some or all areas of the body. Often it results in few bald spots on the scalp of the people. Generally, the size of the spot is of a coin. In few cases, all the hair on the scalp or the body may lose for permanent. Alopecia areata can be considered as an autoimmune disorder resulting from a breach in the immune privilege of the hair follicles. Risk factor for alopecia areata includes family history of the same medical condition. The mechanism involves failure by the body to recognize its own cells due to the destruction of the hair follicle. Till now there is no cure for the condition but some medications are tried for regrowth such as cortisone injection, sunscreen to protect the area being affected from cold and sun, glass if in case eyelashes have been affected or missing. Another type of alopecia andrgenetic which is common in the gender, in men such condition is also recognized as male-pattern baldness.

In this case, hair is lost in a well-defined manner. After some time hairline foam characteristic ‘M’ is often progressing to partial or complete baldness. In the case of females it is a different condition than male. In women, hair becomes thinner than normal from all over the head and often it further leads to total baldness. Androgenetic alopecia in men’s results from some medical conditions such as coronary heart disease, enlargement of the prostate, hypertension and many others.

Global Alopecia Market Overview

Changing lifestyles such as immoderate intake of alcohol and tobacco, and growing stress indices among the people are considered as major factor for rising prevalence of alopecia. Though the epidemiology of the disease is unknown, the genetic factor is considered as a one of the cause and linked to several cases of alopecia. In addition, rise in disposal income of the people and building emphasis on aesthetics are poised to drive the market growth of alopecia products. Furthermore, aging and anomalies also boosting demand for alopecia treatment. Ender also plays important role in disease susceptibility. As per American Hair Loss Association, around 95% of the hair loss in men is due to androgenic alopecia and awareness among consumers is fueling the growth of Global Alopecia Market.

Moreover, the rising prevalence of chronic disorders such as Polycystic Ovary Disease (PCOD), hyperthyroidism, acute stress disorder, hypothyroidism, cancer, lupus, and hypopituitarism are influencing the Global Alopecia Market. New drug and technologies developments in the field such as emergence of rapid-action JAK inhibitors and hair growth stimulation through PRP treatment and pluripotent stem cells are accelerating the growth of Global Alopecia Market. However, high cost of treatment and lack of awareness in underdeveloped countries are anticipated to restrict the growth of Global Alopecia Market. Nevertheless, launch of new products and technologies are expected to generate new opportunities for the Global Alopecia Market during forecasted period.

Global Alopecia Market is segmented based on Disease Type, Sales Channel, Gender, End-User, And Geography.

Alopecia Market, By Disease Type

• Alopecia areata
• Androgenetic alopecia
• Others

Based on Disease Type, Alopecia Market is segmented as Alopecia Areata, Androgenetic Alopecia and Others. Alopecia areata sement is expected to hold largest share in the Alopecia Market. The growth is contributed to the high disease prevalence across the globe and increasing consumer awareness regarding treatments. Also, alopecia is most prevalent in the people who are suffering from autoimmune disorders. Androgenetic alopecia segment is expected to grow at fastest pace due to launch of multiple promising pipeline candidates and significant growth in the incidence rate.

Alopecia Market, By Sales Channel

• OTC
• Prescriptions

Based on Sales Channel, Alopecia Market is bifurcated into OTC and Prescriptions. Among these two segments, Prescriptions segment is expected to hold largest share in the alopecia market by sales channels. Various factors that are driving the growth of segments are cost effective treatment, easy accessibility of therapies and increasing number of approvals for medications.

Alopecia Market, By Gender

• Male
• Female

Based on Gender, Alopecia Market is bifurcated into Male and Female. Among these two segments, male segment are dominating the Alopecia Market, By Gender as androgen is leading cause of androgenic alopecia in men also, and increasing geriatric population across the globe and increasing tobacco intake by people are fueling the growth of male segment.

Alopecia Market, By End-User

• Homecare Setting
• Dermatology Clinics

Based on End-User, Alopecia Market is bifurcated into Homecare Setting and Dermatology Clinics. Among these two, Dermatology clinics segment is dominating the market. The growth is attributed to the increasing number of hair transplantation, and restoration surgeries. Homecare settings segment is also growing due to broadening penetration of laser treatment and rise in regulatory sanctions of homecare products.

Alopecia Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Geography, the Global Alopecia Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America is expected to hold largest market share due to growing advancement in the technology, novel product development and increasing disposal income of the people in the region is fueling the growth of alopecia market in the region. Asia-Pacific is expected to grow at fastest pace over the next few years. Large population base and growing consumer awareness regarding treatments are expected to boost the growth of alopecia market in the region.

Key Players

The “Global Alopecia Market” study report will provide a valuable insight with an emphasis on global market including some of the major players such as Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Cipla Inc., Johnson and Johnson AG, Lexington International LLC, Transitions Hair Pty Ltd., Cirrus Hair Centers, Vita-Cos-Med Klett-Loch GmbH, Capillus, and Follica, Inc.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Global Alopecia Market Size

Source

Recent Posts

Global Alopecia Market Size

Global Alopecia Market Size

/in /by

Global Alopecia Market Size

Alopecia Market was valued at USD 2.68 Billion in 2020 and is projected to reach USD 4.89 Billion by 2028, growing at a CAGR of 7.9% from 2021 to 2028.

Changing lifestyle and rising prevalence of androgenic and areata alopecia across the globe is primary factors for driving the growth of the Global Alopecia Market. Also, the rise in disposable income of the people and growing awareness regarding alopecia treatment is fueling the growth of the Global Alopecia Market. The Global Alopecia Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Alopecia Market Definition

Alopecia areata is also called spot baldness. It is a medical condition in which hair is lost from some or all areas of the body. Often it results in few bald spots on the scalp of the people. Generally, the size of the spot is of a coin. In few cases, all the hair on the scalp or the body may lose for permanent. Alopecia areata can be considered as an autoimmune disorder resulting from a breach in the immune privilege of the hair follicles. Risk factor for alopecia areata includes family history of the same medical condition. The mechanism involves failure by the body to recognize its own cells due to the destruction of the hair follicle. Till now there is no cure for the condition but some medications are tried for regrowth such as cortisone injection, sunscreen to protect the area being affected from cold and sun, glass if in case eyelashes have been affected or missing. Another type of alopecia andrgenetic which is common in the gender, in men such condition is also recognized as male-pattern baldness.

In this case, hair is lost in a well-defined manner. After some time hairline foam characteristic ‘M’ is often progressing to partial or complete baldness. In the case of females it is a different condition than male. In women, hair becomes thinner than normal from all over the head and often it further leads to total baldness. Androgenetic alopecia in men’s results from some medical conditions such as coronary heart disease, enlargement of the prostate, hypertension and many others.

Global Alopecia Market Overview

Changing lifestyles such as immoderate intake of alcohol and tobacco, and growing stress indices among the people are considered as major factor for rising prevalence of alopecia. Though the epidemiology of the disease is unknown, the genetic factor is considered as a one of the cause and linked to several cases of alopecia. In addition, rise in disposal income of the people and building emphasis on aesthetics are poised to drive the market growth of alopecia products. Furthermore, aging and anomalies also boosting demand for alopecia treatment. Ender also plays important role in disease susceptibility. As per American Hair Loss Association, around 95% of the hair loss in men is due to androgenic alopecia and awareness among consumers is fueling the growth of Global Alopecia Market.

Moreover, the rising prevalence of chronic disorders such as Polycystic Ovary Disease (PCOD), hyperthyroidism, acute stress disorder, hypothyroidism, cancer, lupus, and hypopituitarism are influencing the Global Alopecia Market. New drug and technologies developments in the field such as emergence of rapid-action JAK inhibitors and hair growth stimulation through PRP treatment and pluripotent stem cells are accelerating the growth of Global Alopecia Market. However, high cost of treatment and lack of awareness in underdeveloped countries are anticipated to restrict the growth of Global Alopecia Market. Nevertheless, launch of new products and technologies are expected to generate new opportunities for the Global Alopecia Market during forecasted period.

Global Alopecia Market is segmented based on Disease Type, Sales Channel, Gender, End-User, And Geography.

Alopecia Market, By Disease Type

• Alopecia areata
• Androgenetic alopecia
• Others

Based on Disease Type, Alopecia Market is segmented as Alopecia Areata, Androgenetic Alopecia and Others. Alopecia areata sement is expected to hold largest share in the Alopecia Market. The growth is contributed to the high disease prevalence across the globe and increasing consumer awareness regarding treatments. Also, alopecia is most prevalent in the people who are suffering from autoimmune disorders. Androgenetic alopecia segment is expected to grow at fastest pace due to launch of multiple promising pipeline candidates and significant growth in the incidence rate.

Alopecia Market, By Sales Channel

• OTC
• Prescriptions

Based on Sales Channel, Alopecia Market is bifurcated into OTC and Prescriptions. Among these two segments, Prescriptions segment is expected to hold largest share in the alopecia market by sales channels. Various factors that are driving the growth of segments are cost effective treatment, easy accessibility of therapies and increasing number of approvals for medications.

Alopecia Market, By Gender

• Male
• Female

Based on Gender, Alopecia Market is bifurcated into Male and Female. Among these two segments, male segment are dominating the Alopecia Market, By Gender as androgen is leading cause of androgenic alopecia in men also, and increasing geriatric population across the globe and increasing tobacco intake by people are fueling the growth of male segment.

Alopecia Market, By End-User

• Homecare Setting
• Dermatology Clinics

Based on End-User, Alopecia Market is bifurcated into Homecare Setting and Dermatology Clinics. Among these two, Dermatology clinics segment is dominating the market. The growth is attributed to the increasing number of hair transplantation, and restoration surgeries. Homecare settings segment is also growing due to broadening penetration of laser treatment and rise in regulatory sanctions of homecare products.

Alopecia Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Geography, the Global Alopecia Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America is expected to hold largest market share due to growing advancement in the technology, novel product development and increasing disposal income of the people in the region is fueling the growth of alopecia market in the region. Asia-Pacific is expected to grow at fastest pace over the next few years. Large population base and growing consumer awareness regarding treatments are expected to boost the growth of alopecia market in the region.

Key Players

The “Global Alopecia Market” study report will provide a valuable insight with an emphasis on global market including some of the major players such as Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Cipla Inc., Johnson and Johnson AG, Lexington International LLC, Transitions Hair Pty Ltd., Cirrus Hair Centers, Vita-Cos-Med Klett-Loch GmbH, Capillus, and Follica, Inc.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Global Alopecia Market Size

Source

Recent Posts

Stem Cell Alopecia Treatment

Stem Cell Alopecia Treatment

/in /by

Stem Cell Alopecia Treatment market size to expand momentously over 2021-2026

The Research new report on the Stem Cell Alopecia Treatment Market will give its users a comprehensive overview of the overall market post-covid-19, key competitors prevailing in the market, CAGR Value during the forecast period of 2021-2026 coupled with the billion dollars rise in the market share. This report will prove out to be handy for those decision-makers who are looking for new product launches, Niche market penetration, Go to Market strategies and those who are looking for fresh investments post covid -19.

The latest Stem Cell Alopecia Treatment market report predicts the future performance of the industry vertical with respect to key growth determinants, bottlenecks, and rewarding opportunities which are impelling the profitability graph.

As per expert verbatim, the industry is poised to experience notable gains, recording an XX% CAGR over the projected period 2021-2026 The scope of the research literature includes a comprehensive study of this domain at a global as well as regional level for the various industry segments. The document further delineates the competitive hierarchy of the key players. This thorough analysis facilitates stakeholders in effectively charting the possible growth trajectories during the forecast period.

Key inclusions in the Stem Cell Alopecia Treatment market report:

  • Statistical coverage of market size, sales volume, and revenue
  • The growth rate of the market and its sub-markets
  • Opportunity assessment framework
  • Major industry trends
  • Advantages & downsides of direct and indirect sales channels
  • Top traders, dealers, and distributors

Stem Cell Alopecia Treatment market segments covered in the report:

Regional bifurcation: North America, Europe, Asia-Pacific, South America, Middle East & Africa

  • Market analysis at a country-level of every region
  • Revenue amassed, sales garnered, and market share grabbed by each region
  • Forecasts for the revenue and growth rate of each region over the forecast period

Product gamut:

  • Alopecia Areata
  • Alopecia Totalis and Alopecia Universalis
  • Pricing patterns of each product type
  • Market share predictions pertinent to sales netted and revenue accumulated by each product segment

Application spectrum:

  • Hospitals
  • Clinic and Others
  • Product pricing related to the application scope
  • Revenue and sales volume garnered by every application segment over the stipulated timeframe

Competitive dashboard:

  • APEX Biologix
  • Kerastem
  • Riken Research Institute
  • RepliCel and Sanford Burnham Prebys Medical Discovery Institute
  • Basic company details along with information on manufacturing capacity and facilities
  • SWOT analysis of listed company profiles
  • Product and service portfolio of the industry players
  • Records of the pricing model, gross margins, sales, and market share of listed contenders
  • Conclusive overview of market concentration ratio, commercialization rate, and business strategies

Research objectives:

  • Analyzing the outlook of the Stem Cell Alopecia Treatment Market with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Stem Cell Alopecia Treatment Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects
  • Regional and country-level analysis integrating the demand and supply forces that are influencing the growth of the Stem Cell Alopecia Treatment Market.
  • Stem Cell Alopecia Treatment Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Key questions answered in this report – Global Stem Cell Alopecia Treatment Market Data Survey Report 2026

  • What will be the market size and the growth rate in 2021?
  • What are the key factors driving the Global Stem Cell Alopecia Treatment market?
  • Who are the key market players and what are their strategies in the Global Stem Cell Alopecia Treatment market?
  • What are the key market trends impacting the growth of the Global Stem Cell Alopecia Treatment market?
  • What trends, challenges and barriers are influencing its growth into the Stem Cell Alopecia Treatment industry?
  • What are the market opportunities and threats faced by the vendors in the Global Stem Cell Alopecia Treatment market?
  • What are the key outcomes of the five forces analysis of the Stem Cell Alopecia Treatment market?

Stem Cell Alopecia Treatment market size to expand momentously over 2021-2026

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Market Insight and Forecast to 2026

/in /by

Global Alopecia Market Insight and Forecast to 2026

The Alopecia Market has been growing at a faster pace with significant growth rates during the last few years and is anticipated to grow significantly in the forecast period from 2021 to 2027.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 30 major countries.

Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts.

The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

Lifes2good
Sun Pharma.
Dr. Reddy’s Laboratories.
Kirkland Signature
Vitabiotics.
Johnson & Johnson
Alpecin.
Cipla.
Phyto Ales Group

By Type

Oral treatment
Topical treatment
Other treatment

By Application

Male
Female

By Regions/Countries:

North America
United States
Canada
Mexico

East Asia
China
Japan
South Korea

Europe
Germany
United Kingdom
France
Italy

South Asia
India

Southeast Asia
Indonesia
Thailand
Singapore

Middle East
Turkey
Saudi Arabia
Iran

Africa
Nigeria
South Africa

Oceania
Australia

South America

Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years of data history and forecast.

The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have a comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and their impact on the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Alopecia 2015-2020, and development forecast 2021-2026 including industries, major players/suppliers worldwide and market share by regions, with the company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with the base year as 2019.

Key Indicators Analysed

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product

Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2015-2020 & Sales by Product Types.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2021-2026. Further, the report provides breakdown details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.

Market Analysis by Product Type: The report covers the majority of Product Types in the Alopecia Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

Market Analysis by Application Type: Based on the Alopecia Industry and its applications, the market is further sub-segmented into several major Applications of its industry. It provides you with the market size, CAGR & forecast by each industry application.

Market Trends: Market key trends include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis: The report will provide the state of competition in the industry depends on five basic forces: the threat of new entrants, bargaining power of suppliers, bargaining power of buyers, the threat of substitute products or services, and existing industry rivalry.

COVID-19 Impact

The report covers the Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Alopecia market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Global Alopecia Market Insight and Forecast to 2026

 

Alopecia Clinical Trials Review

Alopecia Market Size

/in /by

Alopecia Market Size

The global alopecia market size is expected to reach USD 14.2 billion by 2028. The market is expected to expand at a CAGR of 8.1% from 2021 to 2028. The strong presence of pipeline products and increasing approval for laser-based therapy to treat hair loss conditions are major factors anticipated to drive growth.

Moreover, rising awareness among patients about alopecia and its treatments, increasing government initiatives, supportive regulations & laws, and improvements in healthcare infrastructure are factors expected to propel market growth over the forecast period.

Technological advancements in alopecia treatment are among the key drivers of this market. There are two FDA-approved therapeutics for alopecia-Rogaine and Propecia. There has been an increase in market penetration of generics after patent expiries of both drugs. However, the launch of several promising pipeline candidates over the forecast years such as Xeljanz (tofacitinib), Breezula (clascoterone), Jakafi (ruxolitinib), SM04554, and Lumigan (Bimatoprost) is expected to substantially drive the growth of the market in the near future.

The introduction of low-level laser therapy that helps stimulate hair growth is expected to increase the treatment rate among patients facing hair loss. In addition, the launch of laser caps, helmets, combs, and bands is also anticipated to boost the market growth. For instance, Capillus Laser Cap, iGrow Laser Helmet, iRestore Hair Growth System, and Hairmax Laser devices are some of the technologically advanced products available in the market.

Moreover, the increasing prevalence of diseases such as cancer, Polycystic Ovary Syndrome, and rheumatoid arthritis which are associated with hair loss is also expected to boost the treatment rate of hair loss in the near future. For instance, as per the U.S. Department of Health and Human Services, nearly 5 million women in the U.S. are affected by PCOS. Furthermore, according to the GBD database, the prevalence of PCOS in European countries, such as France, increased from 872,351 to 882,322 in 2018 & 2019, respectively, and in the U.K., the prevalence was found to be 1,134,082 to 1,142,498.

Market players are increasingly forming partnerships and licensing agreements to enhance their product capabilities and promote the outreach of their products. For instance, the iGrow laser system has a partnership with China Central Pharmaceuticals in China. China Central Pharmaceuticals holds exclusive distribution rights over Aspira in the country.

Moreover, Capillus, LLC has collaborated with Svenson, a hair loss treatment clinic to expand the distribution of laser therapy caps in Europe and the Asia Pacific region. The partnership with local players and service providers is expected to increase the adoption of innovative therapy for hair loss treatment.

Additionally, companies are actively participating in scientific conferences and conducting awareness campaigns for creating brand awareness. For instance, in February 2021, Hairmax welcomed Mary Brunetti as the brand ambassador to increase brand awareness about dealing with COVID-19-induced hair loss, as well as hereditary loss. Moreover, it plans to leverage the popularity of the brand ambassador to showcase its target market as to how its products can help regrow and revitalize their hair.

However, reimbursement remains one of the major challenges in this market. Since most of the treatment modalities are considered as not medically essential and are categorized as cosmetic procedures, the treatment for hair loss is generally not covered under insurance plans. Out-of-pocket expenses for alopecia treatment usually include prescription drug copays, frequent doctor visits, and co-insurance for procedures.

Moreover, increasing adoption of substitutes, such as traditional medicines-Ayurvedic, Chinese, and herbal medications may hamper the growth of the market. Based on results from the GlaxoSmithKline plc sponsored survey, around 22.7% of the patients took Chinese medications for treating male androgenetic alopecia in South Korea followed by Taiwan with 22.0% patients.

Alopecia Market Report Highlights

  • In 2020, the alopecia areata segment accounted for the largest revenue share and is anticipated to maintain its dominance over the forecast period
  • Key late-stage pipeline candidates in the treatment of hair loss include: Xeljanz (tofacitinib), Breezula (clascoterone), and SM04554 are expected to fuel the growth in the coming years
  • Alopecia universalis is anticipated to witness the fastest growth during the forecast period owing to the potential pipeline products, such as BNZ-1 (Bioniz Therapeutics), and stem cell educator therapy with minoxidil (Tianhe Stem Cell Biotechnologies, Inc.)
  • North America was the largest market in 2020 mainly due to a high disease prevalence, rising consumer awareness, proactive government measures, technological advancements, and improved healthcare infrastructure
  • Europe held the second-largest market share in 2020 given the high prevalence of AGA i.e., 80% and 50% in both the men and women of the region, respectively

Alopecia Market Size

Source

Recent Posts

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

PRP and Stem cell alopecia

/in /by

U.S. PRP and Stem cell alopecia treatment Market Size

U.S. PRP and Stem cell alopecia treatment market garnered a revenue of USD 129.4 million in the year 2019 globally and is anticipated to reach USD 189.2 million by 2027, growing at a compound annual growth (CAGR) of 4.9% over the forecast period. The market has been observed to be growing at a steady growth rate over the last three years, however, with the impact of the COVID-19 pandemic globally, the business conditions are expected to change. The market size may reduce significantly or increase with a spike depending on how the value chain has been affected in the entire process.

Players that are operational in the market for a longer period of time are anticipated to absorb the sudden changes, losses and increased operational costs better than those who have recently entered the market. The report focuses on numerous factors that are anticipated to impact the market growth directly and indirectly. The report categorically analyses the growth patterns of different segments based on multiple derivation models.

Both the qualitative and quantitative aspects have been covered in the report. The U.S. PRP & Stem cell alopecia treatment market report includes market size, drivers, restraints, opportunities and trends that will help you understand the market dynamics in detail. Moreover, the report will include market estimates & forecasts in terms of revenue for the overall market along with the segments mentioned in the study. The report focuses on providing a holistic view of the entire market scenario from multiple unmatched detailed analyses mentioned in the report.

What to expect from the report?

  • U.S. PRP and Stem cell alopecia treatment Total Available Market (TAM)Size
  • U.S. PRP and Stem cell alopecia treatment Serviceable Available Market (SAM) Size
  • Business Implications of COVID-19 on the Overall Market
  • Market Share/ Revenue Share (%) of Top Market Players in Total Market Size (2019)
  • Market Size & Forecast (2016-2027) At Country & Regional Level, By Segments
  • Overview & Analysis of Key Players Operating in the Market

U.S. PRP and Stem cell alopecia treatment Market Size

Source

Recent Posts

Global Alopecia Treatment Market

Alopecia Treatment Market Investigation

/in /by

Alopecia Treatment Market Investigation Highlighting Grow

The Alopecia Treatment Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.

Alopecia is a condition associated with excessive hair loss or hair damage. Treatment of alopecia plays a key role in modern healthcare, since it aids hair fall prevention and hair regrowth. Unhealthy lifestyle, hormonal imbalance and ageing, are certain the factors causing condition of alopecia.

The global alopecia treatment market size accounted for US$ 7,325.0 million in 2017 and is projected to witness a 4.9% CAGR over the forecast period (2018–2026).

Rising product approvals and launches, along with robust pipelines are expected to drive the global market growth

Rising launches of products along with robust pipelines are expected to propel the global alopecia treatment market over the forecast period. For instance, Fidia Pharma, in November 2018, launched in Italy, Trinov hair growth lotion for growth of hair. Furthermore, Eli Lilly and Company, in September 2018, began clinical trial of phase 2 to assess efficacy and the safety of the drug Baricitinib to treat alopecia areata patients. This study is projected to be over by August 2022.

Increasing initiatives including crowdfunding campaigns along with rising collaborations by market companies is expected to boost the growth of the global alopecia treatment market over the forecast period. For instance, the U.K.-based firm developing restoration therapies cellular hair-HairClone, in 2018, launched its campaign for public crowdfunding, in collaboration with Capital Cell, a company of crowdfunding. Similarly, RepliCel Life Sciences Inc. and Shiseido Company, Limited, in May 2013, declared technology development transfer framework agreement and collaboration for RepliCel’s technology of hair regeneration – RCH-01.

Increasing Alopecia Areata’ prevalence and high focus on development research within North America are expected to boost the growth of the market.

North America region holds the largest share in the global alopecia treatment market, due to rising prevalence of Alopecia Areata and activities of research by market companies. For instance, in 2017, as per the National Alopecia Areata Foundation (NAAF), alopecia areata troubles over 6.8 Mn individuals in the U.S. with 2.1% lifetime risk. Furthermore, the NAAF is focusing on broadening efforts of research through 2 committees, such as the Clinical Research Advisory Council (CRAC) and the Basic Research Advisory Council (BRAC), to develop the Alopecia Areata Treatment Development Program

Rising strategies of acquisition in this region by market companies are key factors expected to drive the growth of the global alopecia treatment market. For instance, Aclaris Therapeutics, Inc., in August 2017, acquired Confluence Life Sciences, Inc. that expanded the immunology and inflammation pipeline of Aclaris with the inclusion of the lead product candidate of Confluence, CDD-450, IL2-inducible T-cell kinase inhibitor, and topical Janus kinase inhibitors.

Furthermore, market players collaborating with regulation authorities along with other governmental organizations is expected to further drive the global North America alopecia treatment market growth during the forecast period. For instance Helomics, Precision Therapeutics Inc., and the National Alopecia Areata Foundation (NAAF), in April, 2019, entered in an agreement for treating people suffering from autoimmune skin disease known as alopecia areata. This agreement was aimed at providing a next-generation patient registry for driving research on novel treatments to people having this disease.

Major Key Players Include In Alopecia Treatment Market: Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., Merck & Co., Inc., Daiichi Sankyo Company, Limited, and Sun Pharmaceutical Industries Ltd.

Main points in Alopecia Treatment Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Alopecia Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Alopecia Treatment Industry Impact

Chapter 2 Global Alopecia Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Alopecia Treatment (Volume and Value) by Type
2.3 Global Alopecia Treatment (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Alopecia Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Alopecia Treatment Market Analysis
Chapter 6 East Asia Alopecia Treatment Market Analysis
Chapter 7 Europe Alopecia Treatment Market Analysis
Chapter 8 South Asia Alopecia Treatment Market Analysis
Chapter 9 Southeast Asia Alopecia Treatment Market Analysis
Chapter 10 Middle East Alopecia Treatment Market Analysis
Chapter 11 Africa Alopecia Treatment Market Analysis
Chapter 12 Oceania Alopecia Treatment Market Analysis
Chapter 13 South America Alopecia Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Alopecia Treatment Business
Chapter 15 Global Alopecia Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions

Alopecia Treatment Market Investigation Highlighting Grow

Source

Recent Posts

Trial of Ritlecitinib in Alopecia Areata

Trial of Ritlecitinib in Alopecia Areata

/in /by

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Pfizer Inc today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and can also affect the face and body.1,2

Ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint of the study, namely the proportion of patients with less than or equal to 20 per cent scalp hair loss after six months of treatment versus placebo.

European Medicines Agency approved treatments,” said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We look forward to bringing this potential new treatment option to patients living with alopecia areata as soon as possible.”

The Phase 2b/3 ALLEGRO trial met the primary efficacy endpoint of improving scalp hair regrowth. All participants entered the study with at least 50 per cent scalp hair loss due to alopecia areata, as measured by the Severity of Alopecia Tool (SALT) score.

A statistically significantly greater proportion of patients who took ritlecitinib 30 mg or 50 mg once-daily, with or without a four-week initial treatment of 200 mg once-daily, had 20 per cent or less scalp hair loss (an absolute SALT score ≤20) after 24 weeks of treatment compared with placebo.

This was followed by a 24-week extension period, during which all participants initially randomized to receive ritlecitinib continued on the same regimen, while participants who received placebo during the initial 24 weeks advanced to one of two regimens: 200 mg for four weeks followed by 50 mg for 20 weeks, or 50 mg for 24 weeks. The study also included a 10 mg dosing arm, which was assessed for dose-ranging and was not tested for statistically significant efficacy compared to placebo.

The safety profile seen with ritlecitinib was consistent with previous studies. Overall, the percentage of patients with adverse events (AEs), serious AEs and discontinuing due to AEs was similar across all treatment groups.

The most common AEs seen in the study were nasopharyngitis, headache and upper respiratory tract infection. There were no major adverse cardiac events (MACE), deaths or opportunistic infections in the trial. Eight patients who were treated with ritlecitinib developed mild to moderate herpes zoster (shingles).

There was one case of pulmonary embolism in the ritlecitinib 50 mg group, which was reported to have occurred on Day 169. There were two malignancies (both breast cancers) reported in the ritlecitinib 50 mg group, which were reported to have occurred on Day 68 and Day 195. Both participants were discontinued from the study.

Full results from this study will be submitted for future scientific publication and presentation. These data, together with data that will become available from ALLEGRO-LT, will form the basis for planned future regulatory filings.

Ritlecitinib is the first in a new investigational class of covalent kinase inhibitors that have high selectivity for Janus kinase 3 (JAK3) and members of the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In laboratory studies, ritlecitinib has been shown to block the activity of signalling molecules and immune cells believed to contribute to loss of hair in people with alopecia areata.3

Ritlecitinib, which was granted Breakthrough Therapy designation from the U.S. FDA for the treatment of alopecia areata in September 2018, is also being evaluated for vitiligo, rheumatoid arthritis, Crohn’s disease and ulcerative colitis.

About the Phase 2b/3 ALLEGRO Trial

This randomized, placebo-controlled, double-blind study investigated ritlecitinib in patients 12 years of age and older with alopecia areata (n=718). Patients included in the study had 50 per cent or more hair loss of the scalp, including patients with alopecia totalis (complete scalp hair loss) and Alopecia Universalis (complete scalp, face and body hair loss), and were experiencing a current episode of alopecia areata that had lasted between six months and ten years. Patients were randomized to receive ritlecitinib 50 mg or 30 mg (with or without one month of initial treatment with once-daily ritlecitinib 200 mg), ritlecitinib 10 mg or placebo.

The primary endpoint was the proportion of patients with scalp hair regrowth in response to ritlecitinib treatment, based on an absolute SALT Score ≤20 at Week 24. SALT is a tool that measures the amount of scalp hair loss. The tool divides the scalp into standard regions, and each region contributes to the total SALT score, which ranges from 0 to 100. A SALT score of 0 corresponds to no scalp hair loss, while a SALT score of 100 corresponds to a total lack of hair on the scalp.4

More information about the Phase 2b/3 ALLEGRO trial can be found at https://www.clinicaltrials.gov under the identifier NCT03732807.

About Alopecia Areata

Alopecia areata is an autoimmune disease characterized by patchy hair loss, almost always involving the scalp, but sometimes also involving the face (eyebrows, eyelashes, beard), the whole scalp or the whole body.1,2 People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out.1,2 The mean age of onset is between 25 and 35 years, but it can also impact older adults, children and adolescents, and is seen in both sexes and all ethnicities.1,2 Alopecia areata is associated with poor health-related quality of life for many patients, who may suffer from serious psychological consequences, including depression and anxiety.1

1 Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clinical, Cosmetic and Investigational Dermatology. 2015;8:397-403. doi:10.2147/CCID.S53985.

2 Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nature reviews Disease primers. 2017;3:17011. doi:10.1038/nrdp.2017.11.

3 King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021 Mar 20:S0190-9622(21)00601-0. doi: 10.1016/j.jaad.2021.03.050.

4 Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines–part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440-447.

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Source

Recent Posts

Alopecia Clinical Trials Review

Alopecia Clinical Trials Review

/in /by

Global Alopecia Clinical Trials Review

The “Alopecia – Global Clinical Trials Review, H2, 2021” clinical trials have been added to the ResearchAndMarkets offering.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on a number of ongoing trials).

The report enhances the decision-making capabilities and helps to create an effective counter-strategies to gain a competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with the reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

  • Report Guidance
  • The Publisher’s Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Alopecia Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix

Companies Mentioned

  • Pfizer Inc
  • Concert Pharmaceuticals Inc
  • Johnson & Johnson
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dr. Reddy’s Laboratories Ltd
  • Almirall SA
  • Applied Biology Inc
  • GlaxoSmithKline Plc

For more information about this clinical trials report visit https://www.researchandmarkets.com

Global Alopecia Clinical Trials Review

Source

Recent Posts

Platelet Rich Plasma and Stem Cell Alopecia

Platelet Rich Plasma and Stem Cell Alopecia

/in /by

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

The Global Platelet Rich Plasma and Stem Cell Alopecia Treatment market exposition comprehensive information that help to build business strategists during the forecast 2021-2027.

Which provides an exhaustive analysis of key market trends & dynamics along with market estimates & forecasts covering major geographies/countries on the basis of historical data. Considering Platelet Rich Plasma and Stem Cell Alopecia Treatment revolutions of the cat1 industry which is major factors of growth.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research sources which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Self-Adhesive Labels includes major supplies & Independent Consultants among others.

The report used two methodologies FPNV Positioning Matrix and the Competitive Strategic Window to assess the figures for all segments and competitive marketplace in terms of product satisfaction and business strategy they follow to sustain in the market.

Pharmaceuticals and Healthcare Development

– India has reached out to top American pharma companies seeking investment in the country’s pharmaceutical and medical devices sector
– The Serum Institute of India will invest 240 million pounds in the UK
– The annual change in WPI notified by the government works out to 0.5% for 2020, the drug prices regulator National Pharmaceutical Pricing Authority said.

Market Segmentation

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market is segmented on the basis of type, application, end-use industry, and region & country.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market by Type

Based on Platelet Rich Plasma and Stem Cell Alopecia Treatment type, the market is divided into type Androgenic Alopecia, Congenital Alopecia, Cicatricial Or Scarring Alopecia. Platelet Rich Plasma and Stem Cell Alopecia Treatment market’s sub-segment is expected to hold the largest market share during the forecast period. Increased demand for high-quality industrial valves in the Pharmaceuticals and Healthcare and other industries.

Also to mitigate the risk of contamination is driving the demand for Platelet Rich Plasma and Stem Cell Alopecia Treatment at present. The growing concern about the market and industry is expected to boost the Platelet Rich Plasma and Stem Cell Alopecia Treatment market in Pharmaceuticals and Healthcare.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market by Application

Based on Platelet Rich Plasma and Stem Cell Alopecia Treatment application, the market is divided into Hospital, Dermatology Clinic, Other. Platelet Rich Plasma and Stem Cell Alopecia Treatment application valves are one of the most basic and indispensable components of today’s modern technological society. A market segment is expected to hold the largest market share in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market.

Global Market Scope and Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size

The scope of the report is to provide a 360-degree view of the market by assessing the entire value chain and analyzing the key Platelet Rich Plasma and Stem Cell Alopecia Treatment market trends from 2021 to 2027 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Country Level Analysis

Most of the countries are estimated to emerge as the fastest growing region and hold the largest market share in the global industrial Platelet Rich Plasma and Stem Cell Alopecia Treatment market, mainly due to Growing industry trends of present situations, which cannot be ignored. Geographically, regional insights have been segmented on the basis of North America, Europe, Asia Pacific, South America and The Middle East And Africa region.

Key Platelet Rich Plasma and Stem Cell Alopecia Treatment market players identified in the report are listed below

Kerastem, Stemcell Technologies, Eclipse, Glofinn Oy., Regen Lab SA, Histogen, RepliCel Life Sciences

Market

Some of the other major highlights of the demand for Platelet Rich Plasma and Stem Cell Alopecia Treatment report include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter’s Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market during the forecast period.

COVID-19 Impact Analysis

– The COVID-19 pandemic had a significant impact on the on-trade segment and Industry.
– Manufacturers are comprehending strategies to revive from the current situation by means of reshaping their sales channels as well as product innovation.
– The duration of the virus outbreak remains a key factor in assessing the overall impact of the pandemic. However, the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry is expected to stabilize after 2021.
– The liquor industry was not impacted severely due to the pandemic.

Key Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Trends

– The report identifies, determines, and forecasts the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market segments based on their type, sub-type, technology used, applications, end-users, and regions.
– Industry to Industry Holds Largest Share in the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market
– It examines the micro-markets based on their growth trends, development patterns, future prospects, and contribution to the overall market.
– Demand from Regional / geographical is Expected to Drive the Growth
– Rising Adoption of Market Segments in the Platelet Rich Plasma and Stem Cell Alopecia Treatment Growth
– North American, Europe is Expected to Witness Higher Growth Rate over the Forecast Period
– It studies the competitive developments such as partnerships and collaborations, mergers and acquisitions (M&A), research and development (R&D) activities, product developments, and expansions in the Global Platelet

Rich Plasma and Stem Cell Alopecia Treatment Market.

Table of Contents

Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market, years considered, and study objectives. Additionally, it touches on the segmentation study provided in the report on the basis of the type of product and application.

Executive Summary: It gives a summary of key studies, market growth rate, competitive landscape, market drivers, trends, and issues, and macroscopic indicators.

Production by Region: Here, the report provides information related to import and export, production, revenue, and key players of all regional markets studied.

Profile of Manufacturers: Each player profiled in this section is studied on the basis of SWOT analysis, their products, production, value, capacity, and other vital factors.

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Growth are segmented on the basis of market type, application, end-user and region.

Based on Type

Androgenic Alopecia
Congenital Alopecia
Cicatricial Or Scarring Alopecia

Based on Application

Hospital
Dermatology Clinic
Other

Regions Covered

Americas
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Chile
Colombia
Rest Of Latin America

Europe
United Kingdom
Germany
France
Italy
Spain
Netherlands
Sweden
Rest of Europe

Asia-Pacific
China
India
Japan
South Korea
Australia
Singapore
Indonesia
Malaysia
Thailand
Philippines,
Vietnam
Rest of Asia-Pacific

The Middle East And Africa
Saudi Arabia
United Arab Emirates
South Africa
Iran
Turkey
Morocco
Nigeria
Algeria
Cameroon
Chad
Congo
Egypt
Kuwait
Rest of LAMEA

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

Source

Recent Posts

Androgenic Alopecia Drug Market

Androgenic Alopecia Drug Market

/in /by

Androgenic Alopecia Drug Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027

Androgenic Alopecia Drug Market Size and Forecasts 2021 to 2027

The Global Androgenic Alopecia Drug Market witnessed a rapid growth in the historic period from 2016 to 2019 and is anticipated to witness significant growth during the forecast period.

Global Androgenic Alopecia Drug Market Size, Trends, Growth, Competitive Landscape and Key Regional Analysis to 2027” offers broad information and understanding of the Androgenic Alopecia Drug markets. The report analyses the Androgenic Alopecia Drug market for the historical (2016–2020) and forecast (2021–2027) periods. The report includes drivers, restraints and opportunities influencing the market, market size analysis with respect to revenue.

The report also provides a snapshot of the competitive landscape of the key players operating in the market along with the percentage market share of the top players. The report has a section on the impact of COVID-19 on the Androgenic Alopecia Drug market at the global and country levels.

This analysis includes demand & supply-side implications of the Androgenic Alopecia Drug market in 2019. The report is built using data and information sourced from primary & secondary research, proprietary databases paid database among others.

Androgenic Alopecia Drug Market Snapshot

Scope of the Androgenic Alopecia Drug Market Report:

This report provides an in-depth analysis of the Global Androgenic Alopecia Drug Market. The market estimates and forecasts provided in the research report are the results of in-depth secondary research coupled with primary interviews and in-house expert opinions. These market estimates and forecasts have been considered by reviewing the impact of various political, social, and economic factors along with the current market scenarios affecting the Androgenic Alopecia Drug market growth

Along with the Androgenic Alopecia Drug market summary, which includes the market dynamics comprising of drivers, restraints, and opportunities the chapter also includes a Porter’s Five Forces analysis which explains: the threat of new entrants, buyers bargaining power, bargaining power of supplier, the threat of substitutes, and competitive rivalry in the Global Androgenic Alopecia Drug Market. Furthermore, the supply chain analysis explains the various participants, such as raw material suppliers, system integrators, distributors, intermediaries and end-users within the ecosystem of the Androgenic Alopecia Drug market. It provides vendor landscape at the global level and summary of the key upcoming projects/ products

Segments Covered in the Androgenic Alopecia Drug Market Report:

This report forecasts revenue growth at global, regional, and country levels and offers an analysis of latest industry developments in each of the sub-segments from 2016 to 2027.

Global Androgenic Alopecia Drug Market, By Product

  • RK-023
  • Refagro
  • RCH-01
  • SM-04554
  • HYG-440
  • Others

Global Androgenic Alopecia Drug Market, By Application

  • Clinic
  • Hospital
  • Home Use

Androgenic Alopecia Drug Market Regional Overview:

The report offers in-depth analysis of the Androgenic Alopecia Drug market at the global, regional (North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa) and key country (the US, Canada, China, India, Japan, South Korea, the U.K., Germany, France, Brazil, Mexico) levels. The market estimates and forecasts for the segmentation mentioned in the study will be provided at regional and country level. The market estimates and forecast will help understand the dominant region in 2020 and will further enlighten the upcoming region that will generate major revenue in the Androgenic Alopecia Drug market.

Global Androgenic Alopecia Drug Market: Competitive Landscape

The market analysis includes a chapter solely dedicated for key players operating in the Global Androgenic Alopecia Drug Market wherein the analysis provide an insight of the business overview, financial statements, product overview, and the strategic initiatives adopted by the market players. The companies mentioned in the study can be customized according to the client’s requirements.

Global Androgenic Alopecia Drug Market, Key Players

  • Allergan, Inc.
  • Histogen, Inc.
  • R-Tech Ueno, Ltd.
  • Hygeia Therapeutics, Inc.
  • SWITCH Biotech LLC
  • Polichem S.A.
  • Kasiak Research Pvt. Ltd.

Key Questions Addressed:

  • Which innovative technology trends are expected over the next seven years?
  • Which sub segment is likely to get the maximum opportunity to grow during the forecast period?
  • Which region is projected to lead with the highest market share by 2027?
  • How are companies instigating organic and inorganic strategies to gain a surge in the market share?

Global Androgenic Alopecia Drug Market: Research Methodology

The research methodology is a mix of primary research, secondary research and industry opinion leaders. Moreover, secondary research comprises of sources such as company annual reports, press releases, and research papers related to the industry. Other sources include government websites, trade journals and associations are also been reviewed for developing business growth strategies in Androgenic Alopecia Drug Market.

Androgenic Alopecia Drug Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027

Source

Recent Posts